Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OLUVENAZA: Olutasidenib, Venetoclax, and Azacitidine in Newly Diagnosed IDH1-Mutated AML
NCT06782542Phase 2Recruiting
- Start
- Mar 2026
- Primary completion
- Mar 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of olutasidenib in acute myeloid leukemia (AML). Primary endpoints: Number of Participants Experiencing Excessive Toxicity at 12 months and Composite Complete Remission at 3 months. Started Mar 2026; status: recruiting.
02
Drugs
olutasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06782542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06782542.